NIH-funded adjuvant for COVAXIN COVID-19 vaccine aids India’s pandemic response

The U.S. National Institutes of Health (NIH) reported this week that a COVAXIN adjuvant they funded, Alhydroxiquim-II, is actively aiding the COVID-19 response efforts in India, boosting the COVAXIN vaccine’s efficacy among the millions who have taken it.

Alhydroxiquim-II was originally discovered and tested by biotech company ViroVax LLC, based in Lawrence, Kansas. It was exclusively supported by the National Institute of Allergy and Infectious Diseases (NIAID) Adjuvant Development Program. Comprising a small molecule attached to the substance Alhydrogel, it travels to lymph nodes to activate cellular receptors and bolster immune response to viruses, boosting immune responses and vaccine efficacy.

“Ending a global pandemic requires a global response,” Dr. Anthony Fauci, NIAID director, said. “I am pleased that a novel vaccine adjuvant developed in the United States with NIAID support is part of an efficacious COVID-19 vaccine available to people in India.”

Also important for discovery is that Alhydroxiquim-II is the first adjuvant in an authorized vaccine to activate the receptors TLR7 and TLR8 successfully. It also stimulates the immune system to actively search for invading pathogens. In return, it offers only mild side effects.

COVAXIN, which has benefited from the adjuvant, is a COVID-19 vaccine developed and manufactured in India and has been distributed to roughly 25 million people so far. In recent months, the nation has become one of those hardest hit by the ongoing pandemic. The vaccine has demonstrated a 78 percent efficacy against symptomatic disease and full efficacy against severe cases, along with 70 percent efficacy against asymptomatic infection. It also appeared to be effective against the Delta variant currently gaining traction worldwide.

Bharat Biotech International Ltd., which makes COVAXIN, has signed a licensing agreement to use Alhydroxiquim-II for its candidate vaccines. That license was expanded during the pandemic to include COVAXIN.

Chris Galford

Recent Posts

Sen. Brown urges passage of legislation sanctioning wide-reaching illicit fentanyl supply chain

While the Fentanyl Eradication and Narcotics Deterrence (FEND) Off Fentanyl Act has made it into…

8 hours ago

White House Council on Supply Chain Resilience to create federal Supply Chain Resilience Center

As a means to protect the U.S. supply chain, the inaugural meeting of the White…

8 hours ago

U.S., U.K. security agencies release joint guidelines for secure AI development

The U.S. Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency (CISA) and the U.K.…

1 day ago

U.S. Coast Guard Cutter Legare returns from nearly 10-week deployment securing maritime borders

After 73 days on patrol, the U.S. Coast Guard Cutter Legare returned to Virginia last…

1 day ago

Boeing eyes production after delivering final MH-139A Grey Wolf test aircraft to U.S. Air Force

Boeing expects to provide its first low rate production aircraft of the MH-139A Grey Wolf…

2 days ago

Department of Defense holds workshop to better understand manufacturing needs, technology opportunities

Assembling its Manufacturing Innovation Institutes (MII) and stakeholders last month, the U.S. Department of Defense…

2 days ago

This website uses cookies.